Clinical Trial Update: To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating afatinib for efficacy and safety in advanced ALTRK-negative esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Peking University | Conditions: Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN